Web Results


A prognostic impact of the PSA doubling time was also reported in another study, demonstrating a 10-year disease-specific survival rate of 30% for patients with a PSA failure and a PSA doubling time ≤6 months vs. 67% and 98% for those with PSA failure and doubling time >6-10 months and >10 months .


We examined serial PSA data from 249 patients with metastatic disease to assess PSA doubling time (PSADT) in hormone-naive prostate cancer (HNPC) and HRPC states. In a subset of patients, the relation of PSADT to Gleason score and survival was studied.


Prostate-specific antigen doubling time (PSADT) of individual patients as they transition from the hormone-naive (HN) to hormone-refractory (HR) states. Calculated PSADT for the subset of patients with known HN and HR PSADTs; Gleason scores and survivals demonstrate a wide range.


The PSA doubling time, from the first post biopsy PSA score in Feb 2018 to the last one in March 2019, taking all the intervening scores into account, is in negative figures, (-) 6.7yrs with a velocity of (-) 1.3ng/ml/yr. Are there any formal guidelines that would govern active surveillance under such conditions?


ing time. The only statistically significant prognostic parameter affecting overall survival was the best PSA response rate to docetaxel chemotherapy being over or under 50%. The most significant parameter that affects the PSA doubling time was the clinical stage at the time of diagnosis. PSA doubling time is not a useful predictive tool for ...


In addition to the accepted parameters of serum PSA level, clinical staging, and pathologic grading and staging, PSA doubling time has emerged as an important factor in the evaluation of men with newly diagnosed prostate cancer or prostate cancer that recurs after treatment.


The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 yr and overall survival (OS) data were immature.


PSA Doubling Time Predicts Metastasis, Mortality Risks in CRPC PSA in Midlife Can Predict Later Risk of Prostate Cancer Mets The median metastasis-free survival (MFS) times differed significantly ...


For instance if the PSA doubles in a period of less than 8 months, by 7 years 54% had metastases, but if the PSA doubling time was slower than 8 months, by 7 years only 7% had developed metastases. In general patients with a delayed, slow rise in the PSA will probably never develop problems and may require no therapy.


Last but not least, data on PSA at BCR, PSA doubling time, family history of aggressive PCa, tumour volume and micro-metastases in lymph nodes were not available for all patients included in our studies. Future well-designed studies could improve our model in terms of predictive power adding these variables. 5. Conclusions